Monoclonal antibody therapeutics (mAb) are available for ordering and can be used to treat eligible non-hospitalized patients who have tested positive for COVID-19 and have mild to moderate symptoms. According to the Centers for Disease Control and Prevention (CDC), these treatments mimic the immune system’s response to SARS-CoV-2 (the infection that causes COVID-19) and are available to eligible patients 12 years and older with a high risk of progressing to severe forms of COVID-19 or being hospitalized. The federal Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (HHS/ASPR) has an ample supply of all COVID-19 monoclonal antibody therapeutic products and is encouraging state and territorial health departments as well as health care providers to continue ordering and using these products. Pause in the distribution of bamlanivimab/etesevimab In June, ASPR paused all distribution of bamlanivimab/etesevimab together and etesevimab alone on a national basis until further notice. In addition, the Food and Drug Administration (FDA) recommends that health care providers nationwide use alternative authorized monoclonal antibody therapies, REGEN-COV (casirivimab and imdevimab) and sotrovimab, and not use bamlanivimab/etesevimab administered together at this time.
0 Comments
Leave a Reply. |
AuthorThe Bureau of Health Care Quality and Compliance (HCQC) licenses medical and other health facilities, child care facilities and personnel, and medical laboratories and personnel in Nevada. HCQC also conducts compliance surveys and takes complaints. Archives
October 2023
Categories
All
|